Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
Nat Microbiol. 2019 Feb;4(2):293-305. doi: 10.1038/s41564-018-0306-4. Epub 2018 Dec 10.
The inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome-the molecular interface between host and microbiota-are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic 'guilt by association' (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome-metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.
炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC),是一种多因素的胃肠道慢性疾病。虽然 IBD 与肠道微生物群的显著变化有关,但肠道代谢组——宿主与微生物群之间的分子界面——的变化却知之甚少。为了弥补这一空白,我们对来自 CD、UC 和非 IBD 对照组患者的横断面粪便样本进行了非靶向代谢组学和 shotgun 宏基因组学分析。代谢组学和宏基因组学的特征与粪便钙卫蛋白水平(肠道炎症的衡量标准)广泛相关。在超过 8000 个测量的代谢物特征中,我们确定了在 IBD 中差异丰富的化学物质和化学类群,包括鞘脂和胆汁酸的富集,以及三酰甘油和四吡咯的耗尽。虽然 > 50%的差异丰富的代谢物特征尚未被描述,但许多可以通过代谢组学的“关联罪责”(与已知代谢物的共变)来赋予推测的作用。宏基因组学特征中的差异丰富的物种和功能反映了 IBD 肠道中氧化应激的适应性,并且与之前的发现一致。然而,通过整合这些数据,我们发现了 122 个差异丰富的物种和特征良好的差异丰富的代谢物之间的稳健关联,表明在 IBD 中可能存在受干扰的机制关系。最后,我们发现基于代谢组学和宏基因组学的 IBD 状态分类器具有很高的准确性,并且与绝大多数个体趋势一样,在独立的验证队列中也有很好的通用性。因此,我们的研究结果提供了对 IBD 中微生物组-代谢组界面的扰动的更深入理解,包括确定了许多潜在的诊断和治疗靶点。